ARAbiraamasundari Ramapalaniappan

Abiraamasundari Ramapalaniappan

*This is an algorithmically generated author record based on publicly available information.

Abiraamasundari Ramapalaniappan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In silico kinase inhibition profiling of BRAF and AKT Signaling in Melanoma Cells with Nuciferine

    by Veerabhuvaneshwari Veerichetty, Iswaryalakshmi Saravanabavan, Abiraamasundari Ramapalaniappan

    The RAS/RAF and PI3K/AKT pathways play a crucial regulatory role and oncogenic mutation of key proteins in these pathways leads to cancer metastasis and chemoresistance. Melanoma is triggered by NRAS and BRAF V600E mutation which causes constitutive activation of the PI3K kinase and BRAF kinase respectively, further leading to oncogenic activation of the AKT kinase and mitogen-activated protein kinase (MAPK). Core regulatory network behind MAPK and AKT cascades interconnect and form feedback loops. This crosstalk between the two pathways plays a vital role in melanoma kinase inhibitor resistance. Nuciferine is found in the plants Nelumbo Nucifera and Nymphaea Caerulea. Nuciferine is the main aporphine alkaloid produced in Nelumbo nucifera. Nuciferine have the best efficiency to remove oxygen free radicals and hydroxyl free radicals. Nuciferine have potent ROS scavenging activity. Nuciferine provokes anti-inflammation, anti-psychotic drug, anti-cancer treatment, and anti-obesity diseases. This in silico analysis results reinforces nuciferine has an effective kinase inhibitor with a potential advantage of evading resistance in melanoma by dual targeting. The residues of the substrate binding pockets were identified using literature search. Molecular docking studies was carried out using AutoDock. Docking studies indicated nuciferine and vemurafenib (reference standard) showed better binding affinity for kinase pockets of Braf V600E, MEK, ERK, PI3K, AKT, mTOR and c-KIT. -7.00Kcal/mol is considered as the cut-off energy for inhibition analysis. Hydrophobic interactions were computed using Biovia. Biovia was used for the graphical representation of protein ligand binding.


  • Open Access

    Comparative Bioavailability and Benefits on Mental Functions of Novel Extended-Release Caffeine Capsules against Immediate-Release Caffeine Capsules: An Open-Label, Randomized, Cross-over, Single-Dose Two-Way Crossover Study

    by Shefali Thanawala, Rajat Shah, R. Abiraamasundari, R. Senthurselvi, Prabakaran Desomayanandam

    Present study aimed compared pharmacokinetic profile of sustained-release CaffXtend® capsules (SR-Caffeine) with immediate-release caffeine capsules (IR-Caffeine), and the effect of SR-caffeine on memory, motivation, concentration, and attention. This open-label, randomized, single-dose, two-treatment, two-sequence, two-period, two-way crossover oral bioavailability study block randomized (1:1) healthy subjects (N = 15) to receive SR-Caffeine (200 mg) and IR-Caffeine (200 mg). Blood samples were collected at 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 and 48 h in each period. Primary study outcome included comparing relative bioavailability of SR-Caffeine 200 mg and IR-Caffeine 200 mg under fasting conditions, and changes in caffeine research visual analogue scale (Caff-VAS) scores (‘relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’, ‘headache’, ‘overall mood’ and ‘mentally fatigued’) were also evaluated. Fifteen subjects completed the study. Mean tmax was 4.08 ± 2.13h for SR-Caffeine compared to 0.83 ± 0.39h for IR-Caffeine, (p < 0.0001). Similarly, mean t½ was 7.07 ± 3.48h for SR-Caffeine compared to 5.78 ± 2.11h for IR-Caffeine (p = 0.04189). However, total exposure was similar for SR-Caffeine and IR-Caffeine (90% CI: 89.89–120.50% to 94.49–123.82% for geometric least square mean of ln-transformed AUC0-t and AUC0-∞). In the Caff-VAS evaluation, the SR-Caffeine group showed significantly better scores for ‘jitteriness’, ‘tiredness’, ‘alertness’ and ‘overall mood’ for 8–12 h than the IR-Caffeine group. No adverse events were reported. Results demonstrated sustained release of caffeine over 24 h from SR-Caffeine as compared to IR-Caffeine, which showed significant improvements in the scores for ‘relaxed’, ‘alertness’ and ‘overall mood’ and significantly lower scores for the parameters-‘jittery’ and ‘tired’ for extended period. Clinical trial registration: CTRI/2021/06/034185